Publications
Targeted PDE4 Inhibition Using PALI-2108 Prodrug as a Novel Therapeutic Strategy in Fibrostenotic Crohn’s Disease
4th Annual Precision Medicine in IBD Summit
April 1, 2026
Oral Locally Bioactivated PDE4 Inhibitor Prodrug PALI-2108 Demonstrates Rapid Clinical, Histologic, and Biomarker Improvement in Ulcerative Colitis: Phase 1b Translational Findings
21st Congress of the European Crohn’s and Colitis Organization (ECCO)
February 18–21, 2026
PALI-2108, Gut-Targeted PDE4 Inhibition with PALI-2108 Demonstrates Rapid Clinical, Histologic, and Biomarker Improvement in Ulcerative Colitis: Translational Findings from a Phase 1 Study
Crohn’s & Colitis Congress 2026
January 22-24, 2026
A Bioinformatic Approach to PALI-2108 Treatment in Ulcerative Colitis Reveals the Potential for Anti-Fibrotic Efficacy with Local PDE4 Inhibition in Intestinal Fibrosis
Digestive Disease Week (DDW) 2025
May 3–6, 2025
PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug, Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model
2025 Crohn’s and Colitis Congress
February 6-8, 2025
Detailing Characteristics of Fibrostenotic Crohn’s Disease Biology & the Potential of a Local PDE4 Inhibitor Prodrug to Minimize Off-Target Effects & Maximize Efficacy
8th Annual Antifibrotic Drug Development (AFDD) Summit
November 21, 2024
Colonic Bioactivation and Potent TNFa Inhibition of PALI-2108 in Human Clinical Studies: A Promising PDE4 Inhibitor Prodrug for the Oral Treatment of Ulcerative Colitis
ACG’s 2024 Annual Scientific Meeting
October 25, 2024
Local Bioactivation and Efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment
Digestive Disease Week (DDW) 2024
May 21, 2024
Advancing PALI-2108: Discovery to Strategic Positioning
IBD Innovate: Product Development for Crohn’s & Colitis™
April 9, 2024